Calif., Feb. 12, 2008 - Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the company has completed patient enrollment in its Phase 1 dose-escalation clinical trial of Alocrest(tm) (vinorelbine liposomes injection, OPTISOME(tm)). This trial was designed to assess the safety, tolerability and preliminary efficacy of Optisomal encapsulated vinorelbine, or Alocrest...
... Alocrest is a novel sphingomyelin/cholesterol liposome-encapsulated vinorelbine tartrate formulation. Vinorelbine, a semi-synthetic vinca alkaloid, is a microtubule inhibitor that has been approved for use as a single agent or in combination with cisplatin for the first-line treatment of advanced non-small cell lung cancer... Hana Biosciences' Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
February
(25)
- AstraZeneca RECENTIN BR24 Non-Small Cell Lung Canc...
- Aerocrine, Chest M.I. market and sell NIOX MINO in...
- N30 Pharma, Successful Initiation of Human Studies...
- Glenmark, USD 15 million as milestone payments fro...
- BioMarck Pharmaceuticals, FDA Agreement on its P...
- ADVENTRX, Complete ANX-530 Pharmacokinetic Data at...
- Hana Biosciences, Top-Line Phase 1 Clinical Trial ...
- Bayer and Onyx , Update on Phase 3 Trial of Nexava...
- Oncothyreon's PX-478, effective in preclinical mod...
- Strativa Pharmaceuticals, Discontinuation of the D...
- VioQuest Pharmaceuticals, Clinical Trial Agreement...
- GSK's Volibris (ambrisentan), EMEA positive opinio...
- UCB and sanofi-aventis, FDA Approves XYZAL® (levoc...
- Pfizer and The Pfizer Foundation, to Support Cance...
- GlaxoSmithKline, EMEA positive opinion for the app...
- Schering-Plough, ASMANEX (R) TWISTHALER(R) (Mometa...
- MedImmune submitted Biologics License Application...
- Pfizer Japan, Manufacturing and Marketing Authoriz...
- CAS Medical Systems, Placement of 50th FORE-SIGHT ...
- Masimo, New National Standard for CO Screening by ...
- Sanofi Pasteur and Statens Serum Institut , develo...
- TOPIGEN's TPI ASM8 , European Phase 2 Clinical Stu...
- GlaxoSmithKline and TB Alliance, Tuberculosis Drug...
- Sepracor and Nycomed : exclusive development, mark...
- EPIX Pharmaceuticals, Collaboration with Cystic Fi...
-
▼
February
(25)